arrow
J

Jayesh B. Majithiya

artios pharma
H指数:19
被引数:1,934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy

SHLD2缺失是Polθ抑制联合放疗的合成易感性

2026-06-120
OA
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
2023-06-1746
OAAI
The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons
2023-04-043
PRE
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta (vol 65, pg 13879, 2022)
2023-02-231
PRE
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
2022-10-0622
PRE
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
2021-12-010
PRE
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Pol θ 抑制剂引起BRCA基因合成致死率和靶向PARP抑制剂抗性

2021-06-17207
OAAI
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation
2015-09-14231
OAAI